The multifaceted nature of myelodysplastic syndromes: Clinical, molecular, and biological prognostic features

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 11, Issue 7, 2013, Pages 877-885

  Greenberg, Peter L ^a  

^a STANFORD CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; BONE MARROW CELL; CLINICAL FEATURE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MYELODYSPLASTIC SYNDROME; PATHOGENESIS; PHENOTYPE; PROGNOSIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84882953089     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2013.0105     Document Type: Review

References (66)

1. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088.
2. Malcovati L, Porta M, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria, a basis for clinical decision making. J Clin Oncol 2005;23:7594-7603.
3. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoringsystem for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503-3510.
4. Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model inmyelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008;113:1351-1361.
5. Della Porta MG, Luca Malcovati L, Strupp C, et al. Risk stratification based on bothdisease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica 2011;96:441-449.
6. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the WHO classificationof myeloid neoplasms and acute leukemia, rationale and important changes. Blood 2009;114:937-951.
7. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of themyelodysplastic syndromes. Br J Haematol 1982;51:189-199.
8. Schanz J, Tüchler H, Solé F, et al. New comprehensive cytogenetic scoring system forprimary myelodysplastic syndromes and oligoblastic AML following MDS derived froman international database merge. J Clin Oncol 2012;30:820-829.
9. Greenberg P, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System for Myelodysplastic Syndromes. Blood 2012;120:2454-2465.
10. Kao JM, McMillan A, Greenberg PL. International MDS risk analysis workshop (IMRAW)/IPSS re-analyzed: impact of cytopenias on clinical outcomes inmyelodysplastic syndromes. Am J Hematol 2008;83:765-770.
11. Malcovati L, Della Porta MG, Strupp C, et al. Impact of the degree of anemia on theoutcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica 2011;96:1433-1440.
12. Sanz GF, Sanz MA, Vallespi T, et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989;74:395-408.
13. Cordoba I, Gonzalez-Porras JR, Such E, et al. The degree of neutropenia has aprognostic impact in low risk myelodysplastic syndrome. Leuk Res 2012;36:287-292.
14. Kantarjian H, Giles F, List A, et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer 2007;109:1705-1714.
15. Aul C, Gattermann N, Heyll A, et al. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 1992;6:52-59.
16. Gonzalez-Porras JR, Cordoba I, Such E, et al. Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome. Cancer 2011;117:5529-5537.
17. Morel P, Declercq C, Hebbar M, et al. Prognostic factors in myelodysplasticsyndromes: critical analysis of the impact of age and gender and failure to identify a very-low-risk group using standard mortality ratio techniques. Br J Haematol 1996;94:116-119.
18. Kuendgen A, Strupp C, Aivado M, et al. Myelodysplastic syndromes in patientsyounger than age 50. J Clin Oncol 2006;24:5358-5365.
19. Nösslinger T, Tüchler H, Germing U, et al. Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. Ann Oncol 2010;21:120-125.
20. Stauder R, Noesslinger T, Pfeilstöcker M, et al. Impact of age and comorbidity in myelodysplastic syndromes. J Natl Compr Canc Netw 2008;6:927-934.
21. Ades L, Lamarque M, Raynaud S, et al. IPSS-r is a powerful tool to evaluate the outcome of MDS patient treated with azacitidine: the GFM experience [abstract]. Blood 2012;120:Abstract 422.
22. Stölzel F, Kramer M, Mohr B, et al. The prognostic impact of the IPSS-R cytogenetic scoring system for patients with MDS allows a risk-stratification for patients with MDS-derived AML [abstract]. Blood 2012;120:Abstract 1715.
23. Messa E, Gioia D, Evangelista A, et al. High predictive value of the IPSS-R: an external analysis of 646 patients from a multiregional Italian MDS registry [abstract]. Blood 2012;120:Abstract 1702.
24. Mishra A, Al Ali NH, Corrales-Yepez M, et al. Validation of the R-IPSS for patients with MDS: therapeutic implications [abstract]. Blood 2012;120:Abstract 2816.
25. Westers TM, Ireland R, Wolfgang Kern W, et al. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia 2012;26:1730-1741.
26. Greenberg PL. Pathogenetic mechanisms underlying myelodysplastic syndrome. In: Greenberg PL, ed. Myelodysplastic Syndromes: Clinical and Biological Advances. Cambridge, England: Cambridge University Press; 2006:63-94.
27. Rajapaksa R, Ginzton N, Rott L, Greenberg PL. Altered oncogene expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 1996;88:4275-4287.
28. Raza A, Mundle S, Iftikhar A, et al. Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis. Am J Hematol 1995;48:143-154.
29. Parker J, Mufti G, Rasool F, et al. The role of apoptosis, proliferation and the Bcl2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 2000;96:3932-3938.
30. Pang WW, Pluvinage JV, Price EA, et al. On hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. Proc Natl Acad Sci (USA) 2013;110:3011-3016.
31. Nilsson L, Astrand-Grundström I, Anderson K, et al. Involvement and functional impairment of the CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. Blood 2002;100:259-267.
32. Nilsson L, Edén P, Olsson E, et al. The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes. Blood 2007;110:3005-3014.
33. Tehranchi R, Woll PS, Anderson K, et al. Persistent malignant stem cells in del(5q) myelodysplasia in remission. N Engl J Med 2010;363:1025-1037.
34. Will B, Zhou L, Vogler TO, et al. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood 2012;120:2076-2086.
35. Bejar R, Levine R, Ebert BL. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol 2011;29:504-515.
36. Rocquain J, Carbuccia N, Trouplin V, et al. Combined mutations of ASXL1, CBL, FLT3, IDH1,IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. Biomed Central Cancer 2010;10:401-408.
37. Sridhar K, Ross D, Tibshirani R, et al. Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression. Blood 2009;114:4847-4858.
38. Mills K, Kohlmann A, Williams PM, et al. Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. Blood 2009;114:1063-1072.
39. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011;364:2496-2506.
40. Jankowska AM, Szpurka H, Tiu RV, et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/ myeloproliferative neoplasms. Blood 2009;113:6403-6410.
41. Kosmider, O, Gelsi-Boyer V, Cheok M, et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes. Blood 2009;114:3285-3291.
42. Papaemmanuil E, Gerstung M, Malcovati, et al. High throughput targeted gene sequencing in 738 myelodysplastic syndromes patients reveals novel oncogenic genes, rare driver mutations and complex molecular signatures with potential impact for patient diagnosis and prognosis in the clinic [abstract]. Blood 2012;120:Abstract LBA-5.
43. Meggendorfer M, Roller A, Haferlach T, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood 2012;120:3080-3088.
44. Abu Kar S, Jankowska A, Makishima H, et al. Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia. Haematologica 2013;98:107-113.
45. Makishima H, Yoshida K, Nguyen N, et al. Somatic mutations in Schinzel-Giedion syndrome gene SETBP1 determine progression in myeloid malignancies [abstract]. Blood 2012;120:Abstract 3.
46. Cristóbal I, Blanco FJ, Garcia-Orti L, et al. SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia. Blood 2010;115:615-625.
47. Mallo M, Cervera J, Schanz J, et al. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia 2011;25:110-120.
48. Jädersten M, Saft L, Smith A, et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol 2011;29:1971-1979.
49. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011;478:64-69.
50. Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011;365:1384-1395.
51. Graubert TA, Shen D, Ding L, et al. 2012. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet 2012;44:53-57.
52. Damm F, Kosmider O, Gelsi-Boyer V, et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood 2012;119:3211-3218.
53. Gondek LP, Tiu R, O'Keefe CL, et al. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 2008;111:1534-1542.
54. Afable MG, Wlodarski M, Makishima H, et al. SNP array-based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes. Blood 2011;117:6876-6884.
55. Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q-syndrome gene by RNA interference screen. Nature 2008;451:335-339.
56. Pellagatti A, Marafioti T, Paterson JC, et al. Induction of p53 and up-regulation of the p53 pathway in the human 5q- syndrome. Blood 2010;115:2721-2723.
57. Czibere A, Burns I, Junge B. Low RPS14 expression is common in myelodysplastic syndromes without 5q- aberration and defines a subgroup of patients with prolonged survival. Haematologica 2009;94:1453-1455.
58. Starczynowski DT, Kuchenbauer F, Argiropoulos B, et al. Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype. Nature Med 2010;16:49-58.
59. Sokol L, Caceres G, Volinia S, et al. Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes. Br J Haematol 2011;153:24-32.
60. Pellagatti A, Cazzola M, Giagounidis A, et al. Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia 2010;24:756-764.
61. Issa P. Epigenetic changes in the myelodysplastic syndrome. Hematol Oncol Clin North Am 2010;24:317-330.
62. Figueroa ME, Skrabanek L, Li Y, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 2009;114:3448-3458.
63. Walter MJ, Ding L, Shen D, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2011;25:1153-1158.
64. Ohyashiki JH, Iwama H, Yahata N, et al. Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes. Clin Cancer Res 1999;5:1155-1160.
65. Lange K, Holm L, Vang Nielsen K, et al. Telomere shortening and chromosomal instability in myelodysplastic syndromes. Genes Chromosomes Cancer 2010;49:260-269.
66. Briatore F, Barrera G, Pizzimenti S, et al. Increase of telomerase activity and hTERT expression in myelodysplastic syndromes. Cancer Biol Ther 2009;8:883-889.